STING1 and inflammatory bowel disease: Incorporating novel strategies, such as targeting the cGAS-STING pathway, alongside established therapies like mesalazine, could pave the way for more effective and less invasive approaches to CAC prevention in high-risk IBD populations, complementing existing surveillance programs.